Thus, the detection of the BRAF V600E mutation in melanoma samples is used to select patients who should respond to BRAF inhibitors (like vemurafenib or dabrafenib), although unfortunately, most metastatic patients with initial tumor response develop resistance [5]. Here, BRAF is linked to melanoma.